The trial will study psilocybin to treat adults with fragile X syndrome. Credit: Priscilla Du Preezon Unsplash.

KGK Science, a wholly owned subsidiary of Wellbeing Digital Sciences, has secured institutional review board (IRB) approval in Canada, to commence a Phase IIA trial to assess the efficacy of psilocybin to treat adults with fragile X syndrome (FXS), the major genetic cause of autism spectrum disorder (ASD).

KGK Science received the approval on behalf of its client Nova Mentis Life Science.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

As part of the trial, KGK Science and Nova will jointly evaluate the effects of microdose psilocybin on the cognitive and autism behaviour spectrum symptoms related to FXS.

The open-label trial will include ten subjects and KGK Science will lead the trial, which aims to start enrolment this year.

Data from the trial will be used to aid Nova’s drug development programme under the Food and Drug Administration (FDA) orphan drug designation, which was secured in 2021.

Previously, Health Canada provided a no objection letter to conduct the trial, which represents one of the first approved studies to allow subjects to take home the drug for dosing.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In February this year, Wellbeing obtained a section 56 exemption, which permits an approved medical professional to prescribe select controlled substances with no legal consequence to treat people with otherwise treatment-resistant conditions.

Wellbeing and KGK Science CEO Najla Guthrie said: “We believe the first-ever Phase IIA clinical trial will be an impactful assessment of the potential of psilocybin in a disorder that truly affects the lives of many families.

“We look forward contributing to the science alongside Nova Mentis.